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ABSTRACT
Background: Temperature distributions resulting from hyperthermia treatment of patients with high-
risk soft-tissue sarcoma (STS) were quantitatively evaluated and globally compared with thermal simu-
lations performed by a treatment planning system. The aim was to test whether the treatment plan-
ning system was able to predict correct temperature distributions.
Methods: Five patients underwent computed tomography (CT) fluoroscopy-guided placement of
tumor catheters used for the interstitial temperature measurements. For the simulations, five 3D
patient models were reconstructed by segmenting the patient CT datasets into different tissues. The
measured and simulated data were evaluated by calculating the temperature change (DT), T90, T50,
T20, Tmean, Tmin and Tmax, as well as the 90th percentile thermal dose (CEM43T90). In order to measure
the agreement between both methods quantitatively, the Bland–Altman analysis was applied.
Results: The absolute difference between measured and simulated temperatures were found to be 2,
6, 1, 4, 5 and 4 C on average for Tmin, Tmax, T90, T50, T20 and Tmean, respectively. Furthermore,
the thermal simulations exhibited relatively higher thermal dose compared to those that were meas-
ured. Finally, the results of the Bland–Altman analysis showed that the mean difference between both
methods was above 2 C which is considered to be clinically unacceptable.
Conclusion: Given the current practical limitations on resolution of calculation grid, tissue properties,
and perfusion information, the software SigmaHyperPlanTM is incapable to produce thermal simula-
tions with sufficient correlation to typically heterogeneous tissue temperatures to be useful for clinical
treatment planning.
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Regional hyperthermia (RHT) is considered a well-established,
nonablative technique that is of clinical value, only when
combined with radiotherapy and/or chemotherapy. The clin-
ical effectiveness of the RHT was proven in several random-
ized clinical trials with various advanced tumors, including
sarcoma, melanoma, head and neck, recurrent breast cancer,
cervical cancer and bladder cancer [1–4]. Elevated tempera-
tures in the range of 40–43 C inside the tumor volume
together with an improved temperature control are essential
for good clinical response, whereby excessive heating of nor-
mal tissues should be prevented [5]. Treatment outcomes,
such as tumor regression and normal tissue effects, depends
on achieved temperature [6,7]; and a thermal dose of 43 C
for 1 h is generally considered optimal [8].
One of the most common established approaches to con-
trol and monitor the tumor temperature during tissue
heating, is the clinical use of minimally invasive or invasive
thermometry. To this end, closed-tip catheters are used, in
which temperature sensors, so-called Bowman thermistors,
were inserted in order to read the temperatures along the
catheter tracks. These catheters are placed either directly in
the treated tumor region, (invasive) or in hollow organs close
to the tumor volume (minimally-invasive), such as the rec-
tum, vagina and bladder. The minimal-invasive thermometry
in the pelvic tumors was as effective as invasive thermal
monitoring [9]. The use of invasive catheters in the tumor is
relatively time-consuming and can be associated with poten-
tial risks such as hemorrhages, infections, acute side effects,
and a low acceptance by patients and physicians [10].
Nonetheless, many clinical studies reported that interstitially
measured temperatures correlate well with clinical endpoints
[11,12]. However, thermometry using these types of tempera-
ture thermistors is normally restricted to selected sites of the
tumor or the normal tissues [13]. An alternative approach is
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magnetic resonance (MR)-based thermometry which offers
the opportunity for noninvasive 3D thermometry by collect-
ing temperature information throughout the patient body
including regions where no catheters are inserted [5].
However, the reliability of the magnetic resonance imaging
(MRI)-based thermometry, in particular in the pelvic and
abdominal region, is generally affected by patient, and organ
motion as well as blood flow [14].
Hyperthermia treatment planning (HTP) can be a very use-
ful instrument to gain accurate information about the 3D
temperature distribution in the patient, as well as to optimize
hyperthermia treatments. With the HTP specific absorption
rate (SAR), and temperature distributions can be estimated in
the patient using numeric calculations [15]. In addition to that,
numerical optimization approaches can be employed to pre-
dict phase-amplitude settings which yield appropriate tumor
tissue heating [16–18]. The accuracy of pretreatment planning
is highly dependent on dielectric and thermal tissue proper-
ties, which are usually taken from literature and feature a
large deviation [19,20], yielding significant quantitative uncer-
tainties in temperature predictions [20–22]. For clinical applica-
tion, Kok et al showed in recent studies that HTP can even be
applied on-line during hyperthermia treatment in order to
improve tumor temperatures in a real-time setting [21,22].
There are some research and commercial software pack-
ages available in several clinical centers which can be used
for HTP [21,23]. However, for the use in clinical hyperthermia
applications, there is a necessity to validate, by utilizing plan-
ning systems, especially with respect to its accuracy for
patient-specific predictions as well as its robustness. The
most widely utilized commercial HTP software is
SigmaHyperPlanTM (Dr. Sennewald Medizintechnik GmbH,
Munich Germany), was specifically designed for RHT and was
employed in this study for all thermal simulations. This has
been clinically validated by comparing simulations with real
measurements of specific absorption rate (SAR) distribution,
which is measured either in phantom or within the patient
in so-called tumor-related reference points [24,25].
Currently, there is no study in the literature investigating
the comparison between interstitial and simulated tempera-
ture distributions in sarcoma patients using the
SigmaHyperPlanTM. Therefore, the aim of this study was firstly
to quantitatively analyze clinical data collected by the invasive
thermometry of patients with high-risk soft-tissue sarcoma
(STS) located in the lower extremity region. In the second
step, the accuracy of the HTP was evaluated by comparing
interstitial temperature data with the simulated data. Here, it
must be emphasized that the ultimate goal of our data evalu-
ation was to test whether the SigmaHyperPlanTM is able to
predict correct temperatures like those measured by invasive
thermometry. The outcome of this study will allow us to
answer the question, whether the SigmaHyperPlanTM can be
reliably utilized for thermal simulations of the STS patients,




The analysis presented in this study covered five patients
with STS in the upper leg region (Table 1). CT scanning of
each patient was performed for HTP using a Somatom
Sensation Open (Siemens Healthineers, Erlangen, Germany)
CT system. The patients were positioned head first, supine
with arms up (similar to the hyperthermia treatment pos-
ition). The CT field of view (FOV) was approximately 60 cm ±
5 cm to cover the entire hyperthermia applicator. The CT
scan parameters were 512 512 acquisition matrix; 4mm ±
1.4mm slice thickness, 120 kV tube voltage and 150mA tube
current. The in-plane resolution of the reconstructed CT
images was 1 1mm2. No contrast agent was administered
during the CT scan. Following the data acquisition, a radiolo-
gist determined the hyperthermia gross tumor volume (HT-
GTV) from the CT (or sometimes MR images) before the
beginning of treatment. The radiologist treatment plan was
used for the entire course of hyperthermia patient treatment.
Implementation of tumor catheters
All consecutive patients, from February 2016 to May 2017,
underwent CT fluoroscopy-guided closed-tip polyethylene
catheter implementation for RHT. All patients, who were
assigned to the closed-tip catheter placement, had high-risk
STS (size >5 cm, histological grade 2 or 3) and were scheduled
for neoadjuvant chemotherapy with RHT. The patients under-
went pre- and post-interventional CT imaging. Multiplanar
reconstructions were utilized to obtain the extent of the
tumor. Furthermore, the reconstructions were employed to
detect the neighboring anatomical structures and to plan the
ideal needle position for catheter placement. For the CT guid-
ance, a 128-slice CT system with CT fluoroscopy (CARE Vision
CT, Siemens; 120 kV, 10–20mA) was used. CT fluoroscopy was
driven with angular beam modulation (HandCARETM,
Siemens). The whole catheter implementation was performed
under periodical single-shot CT fluoroscopic acquisitions only.
Further details about the CT fluoroscopy in RHT are described
by Strobl et al [10]. The procedure of the catheter invasive
placement was carried out by a board-certified radiologist
with an experience of over 5 years in CT-guided interventions.
The patient position and access route was normally chosen
Table 1. Patient characteristic, including the number of the CT slices used for manual and semi-automatic segmentation
of structures.
Patient Gender Diagnosis # of CT slices # of catheters Tumor volume/cm3
1 m leiomyosarcoma 178 3 511
2 f rhabodomysarcoma 120 2 290
3 f pleomorphic sarcoma 100 2 226
4 m Synovial sarcoma 191 1 501
5 m pleomorphic sarcoma 131 2 188
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based on the localization of the tumor. The catheters were
placed at the same distance from each other, especially when
more than one was used. When tumors had both necrotic
and solid parts, where possible, the catheters were positioned
in the solid region. The insertion was then halted when the
needle covered as much as possible of the tumor diameter.
Thereafter, a control CT scan was made to ensure that there
was no active bleeding or other complications and also to ver-
ify a correct position of the tumor catheters. These catheters
were placed one day before the start of the hyperthermia
treatment and remained for two treatments in the tumor, and
they were removed immediately after the second hyperther-
mia treatment. Figure 1 shows the 3D volume rendering of
the tumor catheters of three exemplary patients.
Hyperthermia treatment
The patients were treated inside the SIGMA-Eye applicator
(BSD-2000/3D, Pyrexar Medical Corp., Salt Lake City, UT). The
central point of the HT-GTV of each patient was placed at
the central plane of the applicator. The thermometry data
were collected from the first patient treatment. All channels
of the applicator were set to 100% of the applied power
(Table 2). The maximum power was determined patient-spe-
cific at the first treatment day. The maximum power was
adjusted by considering desired temperature range
(40–43 C) in the tumor, patient feedback regarding com-
plaints and superficial sensation at the patient skin surface.
The target focus for each patient was determined from the
2D CT coordinates (xCT,yCT) of the HT-GTV center. The hyper-
thermia coordinates (xHT,yHT) were then calculated theoretic-
ally, which is based on many focus measurements with our
lamp phantom (width ¼ 380mm, height ¼ 255mm) inside
Sigma 60, Sigma-Eye and Sigma-Eye MR applicators. It turns
out from these phantom measurements that the clinically
useful range of the focus adjustment in the X-axis is from
7 to 7 cm and in the Y-axis from 4 to 4 cm. The hyper-
thermia focus is calculated using the following formula:





The Bowman thermistors with an accuracy of ±0.2 C were
inserted to the tip of the tumor catheters. These thermistors
are transparent for the electromagnetic field, due to their
high resistance of the carbide wires. For the temperature
reading, a clinical thermometry system was employed, con-
sisting of stepping motors which ensured that the thermis-
tors could be pulled out in 5–10mm increments up to
maximum mapping length of 200mm through the catheter
in tumor. Temperatures were continuously recorded within a
time interval of 6min during the RHT. Due to the fact that
temperature distribution in tissues during electromagnetic
radiation is not uniform, it is important to monitor tempera-
tures not only in the HT-GTV, but also in the surrounding
anatomical structures. This has not been considered in this




A model of the SIGMA-Eye applicator in the software
SigmaHyperPlanTM, which was used for the electromagnetic
(EM) as well as thermal simulations, is shown in Figure 2. The
applicator consists of three rings of 24 dipole antenna pairs
that are coupled in 12 channels of two antennas each.
Amplitudes and phases of the hyperthermia signals, which
are fed into each antenna, can be adjusted in order to con-
trol the interference of the radio frequency (RF) field [26].
The arrangement of 24 dipole antennas in the SIGMA-Eye
allows for 3D steering capability. A significant improvement
in the quality of tumor heating can be achieved with the
SIGMA-Eye [27].
Figure 1. 3D volume rendering of three exemplary STS patients with implemented catheters in the tumor.




Treatment HTP_I HTP_II Treatment HTP_I HTP_II
1 (6,2) (0,0) (0,0) 730 613 730
2 (4,0) (0,3) (0,3) 521 451 521
3 (3,1) (4,2) (4,2) 336 334 336
4 (5,1) (8,2) (8,2) 440 696 440
5 (5,5) (5,1) (5,1) 420 604 420
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Patient modeling and EM-simulations
Using the patient CT dataset with a cranial-caudal length of
at least 60 cm, a 3D discrete patient model was recon-
structed by manual/semi-automatic segmentation of different
tissue structures (Figure 2). For all simulations, five organs
(i.e., fat, muscle, bone, bladder and blood vessels) were con-
toured. In addition to that, the HT-GTV was delineated cover-
ing the target volume. The challenge in this study was to
segment the catheters, since each patient underwent two CT
scans collecting two datasets. The first dataset acquired with
large CT-FOV before the catheter placement, whereas the
second dataset collected with small FOV, restricted to the
longitudinal catheter length. In both acquired CT datasets,
the patient positions were different. The first step was to
perform a rigid image registration using the open-source
software elastix [28], in order to match the patient position
in both CT data sets. After that, the catheters were manually
delineated and added to the segmentation of organs. Then,
a 3D patient model was generated from the segmented
structures. Further details on the workflow for the 3D model-
ing of the patient are described by Gellermann et al and
Aklan et al [24,29]. On average, the patient models consisted
of 70 800 tetrahedra, ±19 000 nodes, and 150 700 triangles
with edge lengths of the tetrahedral between 6 and 28mm,
with the dense grid mostly in regions with high tissue con-
trasts and near the antennas. These numbers were prede-
fined in the SigmaHyperPlanTM manual to generate the 3D
patient grid model. Furthermore, other studies employed
similar numbers of tetrahedral [25,29,30], and support our
simulation setting.
The antenna model implemented in the planning system
corresponded to the SIGMA-Eye applicator of the BSD-2000
system for the regional hyperthermia. The biconical dipole
antennas of the applicator were modeled by pairs of metallic
cones (Figure 2), with certain estimates about the neighbor-
ing medium in the feeding point as well as around the
antennas. After successful generation of the patient model,
the grid was extended to incorporate the applicator (anten-
nas and water bolus) and the surrounding air. The selected
applicator was automatically aligned with the patient model,
whereby the tumor center was aligned in the central plane
of the applicator. A water bolus grid (grid size 25mm) for
the SIGMA-Eye, considering the realistic inside bended sur-
face, was then adapted to the positioned patient model with
a grid resolution of 10mm. The bolus was then refilled
with tetrahedrons, and the grid for the surrounding air (grid
size 50mm) was generated. EM cross-coupling between
antennas was to some extent considered in the software
SigmaHyperPlanTM according to its manual.
The finite element (FE) method was utilized for all EM
simulations. The SAR distribution for each point in the
patient model can be obtained by superposition of the EM
fields of all applicator antennas using the solver of SEMCAD-
X (SPAEG, Zurich, Switzerland). The temperature distribution
can then be predicted using the thermal tissue properties
defined in the database of the HTP software [29]. The simula-
tion of the temperature distribution was determined in the
steady state by solving the bioheat-transfer equation on
the same grid. The body temperature for all calculations was
set to 37 C and the bolus temperature to 25 C. Through an
optimization process of amplitudes and phases of the 12-
applicator antenna pairs surrounding the patient, a focus of
the temperature in a predefined target volume can be
achieved, while keeping the healthy tissues within a tolerable
temperature range. More details about the optimization pro-
cess used in the SigmaHyperPlanTM are described by
Sreenivasa et al and Canters et al [25,31].
Two different treatment plans of each patient model were
created to adjust the amplitudes and phases of the applica-
tor in the simulation:
1. HTP_I: Amplitudes and phases were fully optimized by
the HTP.
2. HTP_II: Amplitudes were set manually to 100% after
the optimization similar to the real patient treatment,
while the phases were left optimized. The optimized
power was adapted to the power used in the
patient treatment.
Figure 2. Thermal simulation setup in the software SigmaHyperPlanTM.
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Table 2 summarizes the applicator parameters that were
utilized in both simulations and real patient treatments.
Lamp phantom measurements
The electrical field distributions were measured in an ellip-
tical lamp phantom by applying the three treatment plans
for each patient, namely HTP_I, HTP_II and the plan of the
real patient treatment. The phantom has dimensions of
38 22 cm (long axis, short axis) with a fat-equivalent phan-
tom shell of 1 cm thickness (er ¼ 10, r¼ 0.04 S/m). The
length of the phantom is 100 cm in total with a 50 37 cm
rectangular opening at its back end. The closed front part of
the phantom is 50 cm long. The phantom has an elliptical
base plate with array of approximately 342 electrical field-
sensitive lamps [32].
The phantom was filled with conductive water and posi-
tioned in the applicator with the base plate placed at the
center of the SIGMA-Eye applicator, where the electric field is
highest. For all phantom measurements, lower power of 400
watts was applied to avoid destroying the lamps. 2 D
Photograph images were then shot for each applied plan.
Data analysis
Treatment temperature data
The single steps of the evaluation process of both interstitial
and simulated temperature data is presented in Figure 3. It
must be emphasized that all interstitially measured tempera-
ture data were first collected during the patient treatments
and then compared afterwards to the simulated tempera-
tures. The patient temperature data obtained from the
Bowman thermistors were analyzed with in-house developed
Cþþ code combined with R (The R Foundation for Statistical
Computing, Vienna, Austria) [33]. The temperatures T90, T50
and T20 as well as the cumulative equivalent minutes at
43 C for the T90 temperature (CEM43T90), which is used as
measure for the thermal dose applied, were calculated. The
CEM43T90 is the 10th percentile dose – the thermal dose
that 90% of the rest of measured thermal doses exceed. It is
Figure 3. Flowchart illustrating the evaluation procedure of both treatment and simulated temperature data.
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10% above the minimum thermal dose. Additionally, Tmean,
Tmin and Tmax were also determined. Beyond that, the
temperature rise (DT) for the 90th percentile temperature
(T90) above normal body temperature (37 C) was
calculated as:
DT ¼ T90 37C
The acquired thermal distribution of each tumor catheter
for each patient was visualized in the form of a box plot as a
function of distance. Furthermore, the calculated index tem-
peratures were averaged for each catheter within the thera-
peutic treatment time (from 30min until 90min) and
illustrated as a boxplot, which represented the time-averaged
temperature values for all mapping positions of the catheter.
In order to be able to compare the simulation to the real
patient treatment, the index temperatures in Figure 4 were
averaged within the steady-state treatment time, at which
the temperatures in the thermal simulations were in principle
calculated.
Simulation temperature data
To evaluate the simulated data in the same manner as the
measured data, only the simulated temperature values along
the tumor catheter were obtained by applying a mask con-
sisting of only the segmented catheters to the 3D simulated
thermal maps of the patient model. The T90, T50, T20, Tmin,
Tmax and Tmean were determined using MATLAB 2012 b a
(MathWorks, Inc., Natick, Massachusetts, US). The difference
of the index temperatures between simulation and real
patient treatment (within the steady state treatment time)
was determined using the following formula:
D Cð Þ ¼ jTtreamentTsimulationj
Moreover, the DT of the simulated temperatures and its
difference were also computed, where the treatment data
was taken as a reference.
For better measuring the agreement between both meth-
ods, Bland–Altman [34] plots of the temperature were cre-
ated using temperature data from all patients. The
Bland–Altman approach includes plotting differences
between the results of both approaches as a function of
averages between them. Such representation is visually more
informative than calculating the relative difference. The aver-
age (m) and standard deviation (r) of the differences
between two methods were determined. The values of mþ
2r and m 2r were calculated in the confidence interval of
95%. In accordance with the suggestion of Bland and Altman
and of clinical reasoning, differences beyond m62r could
be judged clinically important. These values are used to
make a decision on whether the differences between the
interstitial and simulation temperature data are important
and if they are not, then both methods may be used
interchangeably.
Results
The results of the invasive thermometry of the five patients
indicated different temperature distributions along the tumor
catheters, as shown in Figures 4 and 5. The heating of the
sarcoma tumor tissues showed inhomogeneous distributions
apart from the tumor volume and location.
Considering the temperature distribution of the first
patient, the temperatures at the tumor margin were signifi-
cantly lower than those observed in the catheter position of
3–9 cm, as shown in Figure 4. After reviewing the patient CT
images, it was seen that a relatively large blood vessel was
located close to the tip of the tumor catheters. The tempera-
tures of the tumor tissues with probably less or even no
blood circulation were substantially higher than at the tumor
rim. Therefore, the CEM43T90 of this treatment was found to
be low, as reported in Table 3. Although the power applied
(730 watts) for this patient treatment was considered be
higher compared to other patient treatments. A similar
observation was seen in the temperature data of the second
patient. The thermometry showed heterogeneous tempera-
tures in both tumor catheters, where catheter #1 exhibited
higher temperatures above 44 C than catheter #2, as illus-
trated in Figure 5. Conversely, the third patient’s treatment
featured essentially a higher thermal dose with a lower
power of 336 watts, measuring higher temperatures due to
the large amount of liquid inside the tumor. From that, it
can be stated that aqueous parts of the tumor in RHT
are fast to heat. This was clearly seen during the treatment,
whereby the therapeutic temperature of 43 C was
reached in the first five minutes of the heating process.
Furthermore, the temperature during the transition between
tumor and muscle tissues dropped down to approximately
40 C from 44 C in the catheter position of 10–12 cm.
The thermal dose of this patient treatment was also signifi-
cantly high.
The fourth patient showed temperature fluctuation along
the tumor catheter. The tumor of this patient was less per-
fused and hence clear temperature gradients were seen with
thermal dose of 1.5min. The last patient, however, showed
an interesting temperature behavior, when the sensor passed
over the tumor, in the catheter position of 0–2 cm, into the
muscular tissues in the distance from 3 to 8 cm. The meas-
ured temperature inside the tumor was around 42 C and
was about 39 C inside the muscles. The thermal dose was
almost similar to the first patient treatment due to the effect
of the blood perfusion. The temperature change (DT) was on
average 3 C in all patients, except in the third patient where
a higher temperature increase of nearly 5 C was observed,
as listed in Table 4.
On the other hand, the thermal simulations showed a
considerable variability in the temperature predictions
as well as in the calculated thermal dose, as reported in
Tables 3, 4, 5 and 6. It can be noticed that predicted temper-
atures up to 49 C were observed among the simulation
results. The 3D simulated thermal maps, overlaid on the ana-
tomical coronal CT image, commonly feature inhomogen-
eous distribution across the 3D modeled patients, as
presented in Figure 6. Furthermore, the thermal maps of
patients 1, 2, 3 and 4 show a slight temperature increase in
the healthy tissues, which might be interpreted as critical
hot spots. This may have potentially occurred because of the
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location of the tumors to the high-density bone structures,
leading to higher reflection and/or absorption of the electro-
magnetic waves. Such details about the development of hot
spots in the healthy tissues were not feasible with the data
of invasive thermometry due to the restriction of the number
of placed catheters. The simulations of the HPT_II (Table 6),
where the power amplitudes of the modeled applicator were
kept similar to the patient treatments, did not significantly
Figure 4. Measured temperatures along the tumor catheters for all treated patients. Note that the height of each boxplot represents the measured values over the
entire treatment time for each catheter position. The red points are the calculated mean values and the black bold line in the boxplot gives the median value. The
position 0 cm means that the sensor was located at the catheter tip. The temperature mapping was in 1 cm steps.
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differ to the results of the HTP_I (Table 5). The absolute dif-
ference between measured and simulated temperatures
were found to be 2, 6, 1, 4, 5 and 4 C on average
(Tables 7 and 8) for Tmin, Tmax, T90, T50, T20 and Tmean,
respectively. A smaller temperature difference in the T90 was
seen. Moreover, the difference in the temperature change of
T90 showed deviation in the range of 1 to 4 C from the
measured temperatures as shown in Table 9.
Figure 7 uncovers the fundamental difference between
patient treatments and thermal simulations, where the
Figure 5. Calculated temperatures using the data from Figure 1. Note that the width of the boxplot reflects the time-averaged temperature values for all mapping
positions. The red point is the computed mean value.
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electrical field distributions of all three plans were measured
using the lamp phantom. The phantom measurements were
performed inside the SIGMA-Eye applicator with a power
application of 400 watts. The results indicated that the distri-
butions of both thermal simulations drifted significantly in
their distribution form as well as the position of hot spot,
when they are compared to those of the real patient treat-
ments. Furthermore, the measured focuses of the thermal
simulations were found to have a large divergence to those
of patient treatments. In order to measure the agreement
between both methods quantitatively, the Bland-Altman
method was applied by calculating the differences and aver-
ages of the temperatures. Figures 8 and 9 show the results
of the Bland–Altman quantitative analysis where the mean of
the differences lay between 5 and 2 C for HTP_I and
between .4 and 0.1 C for HTP_II. In addition, the correl-
ation coefficients between both approaches seem to be poor
in all temperatures (Figure 7). While the standard deviation
of the differences is in the range of 1 to 3 C for both
thermal simulations, the lower confidence limits m 2r
ranged from 1 to 11 C and the upper confidence limits
mþ 2r from 2 to 5 C for HTP_I. For the HTP_II, the corre-
sponding results of m 2r was between 1 and 11 C
and of mþ 2r it was in the range of 2 and 5 C. In gen-
eral, the HTP_I featured larger differences than HTP_II.
Discussion
This study demonstrated a global comparison between inva-
sive thermometry and thermal simulations. The evaluation
was performed using five high-risk STS patients with cathe-
ters placed in the tumor. The software SigmaHyperPlanTM
was utilized for the thermal simulations. The accuracy of the
SigmaHyperPlanTM modeling with measurements has been
systematically investigated in previous studies [24,25].
Gellermann et al assessed the clinical practicability and
accuracy of the planning software, and found that the bias
between the absolute measured and simulated SAR was
Table 3. Thermal dose (CEM43T90) values for both patient treatments and thermal simulations.
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5
Catheter
1 2 3 1 2 1 2 1 1 2
HTP_I 3.8 3.8 0.9 0.2 0.2 0.2 0.9 0.9 15 0.9
HTP_II 3.8 0.9 0.2 0.2 0.2 60 3.8 0.2 3.8 3.8
Treatment 0.2 0.3 0.6 2.9 0.3 30 55 1.4 0.1 0.2
Table 4. Temperature change (DT) of T90 above the patient body temperature of 37 C.
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5
Catheter
1 2 3 1 2 1 2 1 1 2
HTP_I 4 4 3 2 2 2 3 3 5 3
HTP_II 4 3 2 2 2 6 4 2 4 4
Treatment 2 2 3 3 2 5 6 3 3 3
Table 5. Temperatures obtained from the HTP_I. Note that the core body temperature is 37 C.
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5
Catheter
1 2 3 1 2 1 2 1 1 2
Tmin 38 39 37 37 37 40 38 38 38 37
Tmax 45 48 48 48 48 46 43 49 48 48
T90 41 41 40 39 39 39 40 40 42 40
T50 44 46 45 44 44 43 41 46 47 48
T20 44 48 47 47 47 45 42 48 48 48
Tmean 43 45 45 43 43 43 42 45 46 46
Table 6. Temperatures calculated from the thermal simulation HTP_II.
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5
Catheter
1 2 3 1 2 1 2 1 1 2
Tmin 37 38 37 37 37 38 39 40 37 37
Tmax 46 47 46 48 47 49 49 47 48 48
T90 41 40 39 39 39 43 41 39 41 41
T50 44 44 43 46 43 47 46 44 46 46
T20 45 47 44 47 45 48 48 45 48 47
Tmean 44 44 42 45 42 46 46 43 45 45
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±20%. Sreenivasa et al. verified the software by including 30
patients with cervical, rectal and prostate cancers and
showed a good correlation between model calculations and
clinical data regarding the temperature distribution in these
tumors [25]. She concluded that the software delivers valu-
able information, not only for pre- and clinical practice, but
also for further technological improvements. In our study,
the accuracy of the SigmaHyperPlanTM was evaluated with
direct measured temperatures inside the HT-GTV using clin-
ical data of five STS patients.
In spite of using a very limited number of tumor catheters
in each patient, the invasive thermometry provided import-
ant clinical details about the tumor behavior with different
types of sarcoma tumors. The results showed that the tem-
perature increase inside the tumors is generally dependent
on following factors: (1) Anatomical heterogeneity within the
tumor tissues resulting into different dielectric properties; (2)
Inter- and intratissue tumor perfusion under thermal stress
conditions; (3) Location of blood vessels related to the tumor
volume. The lower temperatures observed at the tumor mar-
gin (Figure 4 in patients 1 and 2) compared to the tumor
center are probably caused by a decrease of the blood perfu-
sion due to the adjacent hyperperfused muscle, the so-called
steal-effect [14]. However, temperatures were substantially
higher in regions of low or negligible perfusion, such as in
necrotic tumor. Increased perfusion in the muscle tissues
induced a reduction of the measured temperature during
RHT, as seen in patient 3 (Figure 7). Blood perfusion works as
cooling mechanisms in addition to thermal conduction and
water bolus cooling, which are not taken into account in the
HTP and may have a large effect on the temperature. The
sarcoma tumors usually have very heterogeneous and cha-
otic vessel networks with various perfusion changes leading
to heterogeneous temperature distributions. Perfusion meas-
urements using the MRI technique could be very useful to
monitor the perfusion effects during the RHT treatments
[13,14]. Further, the sarcoma tumors with a relative large
amount of watery collection quickly reached the therapeutic
Figure 6. Coronal cross-sections thermal maps, overlaid on CT images, of the five STS patients generated from the HTP_I. The maps show relative inhomogeneous
temperature distributions within the HT-GTV. Note that some hot spots are developed either within the muscle tissue or close to the bone.
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temperature (Figure 4, patient 3). Such watery collections
feature higher electrical conductivity as well as lower perfu-
sion in comparison to the solid parts of the sarcoma tumor
resulting in a relative rapid heating-up.
The results of the thermal dose CEM43T90 (Table 3) of all
patients, except patient 3, show that the values are quite
low (0.2–3min) within the tumor catheters. In patient 3, how-
ever, the CEM43T903 was higher and found to be 29–55min,
despite a relative low applied power. This is an indication
that tissue properties of the tumor have a significant impact
on the thermal response to the RF energies. For instance,
the tumor of patient 3 featured a relative high liquid fraction,
which was observed during both CT imaging and catheter
implementation. The tumor appeared to progress during RHT
therapy, and a surgical procedure was performed prematurely.
The result of the pathological analysis showed a pseudo-
progression due to a volume increase caused by enclosed
bleeding. Furthermore, extensive necrosis (>90%) was found.
Interestingly, the pathological response (tumor necrosis rate
>90%) showed a significant correlation with CEM43T90 in the
tumor volume. On the other hand, smaller CEM43T90 values
in non-responders were likely associated with a higher tumor
perfusion rate and consequently lower temperatures. In
patient 1, neoadjuvant chemotherapy was planned followed
by pathologic assessment, which revealed a central necrotic
component of 20–30%. However, in order to make a clear
statement about the correlation between CEM43T90 and
necrosis in the tumor in this study, all patient treatments from
the start of the therapy to the time of surgery should be con-
sidered, which is beyond the scope of this study.
The interstitial temperature measurements could be influ-
enced by the thermal mapping system which provides only
a limited spatial temperature resolution. It has the drawback
that only temperature data will be successively acquired at a
predetermined distance, so that no data can be acquired
during the movement phase of the thermistors. Moreover,
the thermal mapping device is a mechanical system consist-
ing of a rotary motor, which in turn has a measuring uncer-
tainty and thus inaccurate position reproducibility. This
would restrict the measuring precision of the temperature
measurements. Furthermore, the simulation and the meas-
ured temperatures were compared only as distribution and
not at individual points along each catheter due to the large
tetrahedron dimensions used in the calculation grid.
Additionally, the invasive tumor catheters have a limitation
in measuring hot spots outside the HT-GTV, which normally
occur at the surface of two different tissue structures. The
evaluation of the occurrence and behavior of possible hot
Table 7. Temperature differences between patient treatment and thermal simulation HTP_I.
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5
D ðCÞ
Catheter
1 2 3 1 2 1 2 1 1 2
Tmin 1 0 3 3 1 2 5 1 2 3
Tmax 4 8 7 5 8 3 1 7 7 7
T90 2 2 0 1 1 3 3 0 2 0
T50 4 6 4 2 5 1 2 5 6 8
T20 4 8 6 5 7 3 2 7 7 7
Tmean 3 5 4 2 4 1 1 4 5 6
Table 8. Temperature differences between patient treatment and thermal simulation HTP_II.
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5
D ðCÞ
Catheter
1 2 3 1 2 1 2 1 1 2
Tmin 2 2 2 3 1 4 6 2 3 3
Tmax 5 7 5 5 7 6 5 5 7 7
T90 2 1 1 1 1 1 2 1 1 1
T50 4 4 2 4 4 5 3 3 5 6
T20 5 7 3 5 5 6 5 4 7 6
Tmean 4 4 1 4 3 4 3 2 4 5
Table 9. Differences of DT for both thermal simulations, where the patient treatment served as a reference.
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5
D ðCÞ
Catheter
1 2 3 1 2 1 2 1 1 2
HPT_I 4 4 3 2 2 2 3 3 5 3
HTP_II 4 3 2 2 2 6 4 2 4 4
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spots was neglected in this study due to the absence of the
invasive catheters in the normal tissues, which was clinically
not feasible. Moreover, location of these invasive catheters
could be changed from the implantation day until the first
hyperthermia treatment, as these catheters were fixed using
filaments attached to the patient skin. Such catheter mis-
alignments could happen during the patient sleep phase
and movement, or even when the tumor is predominantly
composed of fluid tissue (e.g., patient 3). This effect would
clearly impact the results of this study, since the position of
the catheters was taken from the CT dataset directly after
the implementation. The initial CT position of the catheter
could not be ensured at the day of the hyperthermia treat-
ment, in most of the clinical cases. A new CT scan to verify
the correct catheter positions was not possible in the clin-
ical routine.
The thermal simulations exhibited overall higher predicted
temperatures than the invasive thermometry. Particularly
questionable temperatures were those that were higher
than 45 C. Moreover, the temperature rise of simulated tem-
peratures was substantially higher than those observed dur-
ing the real patient treatments (Table 4). The deviation
between thermal simulations and real patient treatments
was in the range of 2 C lower and 6 C higher (Figures 8
and 9, Tables 7 and 8). The observed difference is clinically
not acceptable and thus both approaches should not be
used interchangeably. Nevertheless, the results of the
invasive thermometry revealed important observations that
help to practically improve the accuracy of the HTP, although
few catheters were placed in the tumor. These could largely
enhance the accuracy of thermal simulations with the
SigmaHyperPlanTM. One of these observations is inter- and
intratissue tumor perfusion under thermal stress conditions.
Heat exchange between blood vessels and tissue strongly
depends on the flow rate, which can increase considerably
during RHT [35] depending on the local temperature rise
and the physical condition of the patient. To this end, a tem-
perature dependent perfusion model instead of using a glo-
bal value for the blood circulation, which is the case in the
SigmaHyperPlanTM, might be helpful to further improve the
temperature predictions [17]. A previous study reported that
ignoring the temperature dependence of the perfusion can
lead to a clear overestimation of the absolute thermal dose
that can be delivered [36]. Therefore, modeling using realistic
3 D vessel networks is important for accurate absolute tem-
perature predictions, since the Pennes model does not take
into account the local thermal impact of the vasculature and
the direction of the blood flow. One study in the literature
tried to implement such an accurate realistic 3 D vessel net-
works into the HTP system, showing that the feasibility of
online temperature-based simulations with such networks
will lead to improvement of tumor temperatures [37].
However, further research investigation is required to assess
the benefit of such adaptive treatment planning system and
Figure 7. 2D Photograph images of the lamp phantom positioned inside the SIGMA-Eye applicator, where the applicator settings of patient treatment, HTP_I and
HTP_II were applied. The hot spot in the phantom presents the 2D electrical field distributions using 400 watts for all phantom measurements. Note that the field
distributions of HPT_I and HTP_II feature a significant deviation with respect to the shape of the distribution and the hot spot position, when they compared to
the treatment settings.
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whether the possible advantage justifies the extra patient
burden and clinical workload. From the results of the inva-
sive thermometry, it can also be observed that an accurate
segmentation of the target volume into different compart-
ments is essential, which consider necrotic, solid and liquid
tissues. The different segmented tumor tissues should be
then assigned to corresponding dielectric properties. This
would mimic a realistic tumor composition and help to
reduce the difference between both HTP and real patient
treatment. The existing dielectric (i.e., permittivity and effect-
ive conductivity) and thermal (i.e., blood perfusion, thermal
conductivity, heat capacity, density, and metabolic heat gen-
eration) tissue properties show a large variability of approxi-
mately 50%, but patient-specific tissue properties are not
available and, therefore, average literature values are cur-
rently utilized for the simulations with the SigmaHyperPlanTM
[20,38]. These uncertainties in the tissue properties might
explain why the software is not quantitatively reliable.
Recent research projects focus of further improvement of the
HTP predictions by reconstruction of patient-specific dielec-
tric properties with the help of MR-based dielectric imaging
and advanced thermal modeling using temperature-depend-
ent perfusion and discrete vasculature [17,39,40]. The MR-
based dielectric imaging will potentially improve the reliabil-
ity of the SAR predictions, which are also input for thermal
simulations.
There are a series of uncertainties in the HTP that might
lead to suboptimal treatment settings and thus would add
Figure 8. Bland–Altman plot with the corresponding correlation coefficient (r) between the real patient treatment and thermal simulation HTP_I. The solid line
shows the mean m of differences between both methods and the thin dashed lines show m62r of confidence interval of 95%, where r the standard deviation of
the differences. Note that values with the same differences will be plotted on the top of each other.
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further error to the thermal simulations. One of these uncer-
tainties is the grid resolution of the 3D patient model. The
grid resolution used in this study was 10mm for the patient
model, 25mm for the water bolus and 50mm for the air,
which could be reduced to potentially improve the tempera-
ture predictions. With such rough resolution, structure infor-
mation may be lost, particularly at the boundaries between
the segmented regions, that is, at the tissue interfaces. Finer
anatomical details (such as tissue physiology as well as
arteries and veins) needed for the perfusion modeling, are
strongly affected by a rough resolution and thus EM and
thermal simulations would not be expected to be accurate
enough [15]. High grid resolution may be expected to
improve the accuracy and reliability of the HTP in routine
clinical practice. Another uncertainty is the observer
variability in delineating the HT-GTV and organs at risk in
terms of segmentation accuracy and temperature predic-
tions. The segmentation variations have a statistically signifi-
cant impact on the temperature coverage of the target in
RHT [41]. This might also influence the results of the plan-
ning calculations. Another uncertainty is the patient position,
since the patient normally lies on a flat table during the CT
imaging with their legs elevated. While the applicator model
(Figure 2) available in the simulation is optimal, this does not
necessarily reflect reality. For example, fine individual adjust-
ments of the real hyperthermia applicator are necessary,
which will not be taken into account in the thermal simula-
tions. The use of an optimization method could also induce
an uncertainty to the HTP, which aims for higher tempera-
tures inside the tumor volume and lower temperatures in
Figure 9. Bland–Altman plot with the corresponding correlation coefficient (r) between the real patient treatment and thermal simulation HTP_II.
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the surrounding healthy tissues. The predicted temperatures
might be influenced by the accuracy of those optimization
algorithms [18,42,43].
The electrical field distributions of the third patient were
to some extent similar inside the lamp phantom (Figure 7)
for simulation and treatment. Therefore, the simulation-based
treatment plan was applied in the first 30min of the second
real patient treatment, where the temperature data of the
invasive thermometry were taken as reference in order to
assess the reliability of the HTP. In fact, low temperatures
were observed below 40 C, while the interstitial measure-
ments in the first treatment showed, however, higher tem-
peratures in the tumor above 44 C for the same treatment
time. For this reason, the simulation-based treatment plans
of other patients were not applied for the real patient treat-
ments. Since our treatment facility has more than three deca-
des of experience in performing regional and superficial
hyperthermia using invasive thermometry in sarcoma tumors,
the amplitude steering as well as the power setting for each
individual patient is based on our empirical knowledge and
clinical long-term experience. A reliable and accurate treat-
ment planning system, which mimics a real hyperthermia
patient treatment, would potentially improve the quality of
hyperthermia treatment and thus the clinical outcome. While
HTP with current limitations on spatial resolution of calcula-
tion grid and tissue properties is not able to provide precise
patient specific treatment planning, there are other uses for
the SigmaHyperPlanTM. This planning tool helps us inherently
by investigating the impact of metal implants, patient mispo-
sitioning, as well as by comparing the relative heating effect-
iveness of different applicator settings. Furthermore, it is a
useful tool for predicting the treatment hot spot locations in
order to distinguish between patients who should be easy to
heat or difficult to heat.
Finally, all these mentioned uncertainties could be pos-
sible sources for the difference between the invasive therm-
ometry and the thermal simulations in this study, which
focused on sarcoma tumors in the extremity region. The
evaluation in this study had a low number of patients
(n¼ 5). This is due to the fact that invasive thermometry has
a very low acceptance rate by hyperthermia patients.
Conclusion
This study demonstrates that the global difference between
invasive thermometry and thermal simulations of temperature
distributions in sarcoma tumors is large and clinically
unacceptable for routine treatment planning. Given the cur-
rent practical limitations on resolution of calculation grid and
tissue properties as well as perfusion information, the software
SigmaHyperPlanTM is incapable to produce thermal simula-
tions with sufficient correlation to typically heterogeneous tis-
sue temperatures to be useful for clinical treatment planning.
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